Table 3 Efficacy endpoints in evaluable populations
Parameter | Elacestrant dose cohort | ||
|---|---|---|---|
200/400 mg | 400 mg | Overall | |
Response | N = 4 | N = 5 | N = 9 |
ORR, % | 0 | 20.0 | 11.1 |
Partial response, n (%) | 0 | 1 (20.0) | 1 (11.1) |
Duration of response, weeks | – | 22 | 22 |
Time to response, weeks | – | 7.9 | 7.9 |
Stable disease, n (%) | 2 (50.0) | 3 (60.0) | 5 (55.6) |
Progressive disease, n (%) | 2 (50.0) | 1 (20.0) | 3 (33.3) |
CBR | N = 6 | N = 7 | N = 13 |
16 weeks, n (%) | 3 (50.0) | 4 (57.1) | 7 (53.8) |
24 weeks, n (%) | 1 (16.7) | 3 (42.9) | 4 (30.8) |
Median PFS (95% CI), months | 3.6 (0.7, 17.9) | 6.9 (0.7, NA) | 5.3 (1.7 17.9) |